163 related articles for article (PubMed ID: 25320244)
1. Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase.
Steinhardt JJ; Peroutka RJ; Mazan-Mamczarz K; Chen Q; Houng S; Robles C; Barth RN; DuBose J; Bruns B; Tesoriero R; Stein D; Fang R; Hanna N; Pasley J; Rodriguez C; Kligman MD; Bradley M; Rabin J; Shackelford S; Dai B; Landon AL; Scalea T; Livak F; Gartenhaus RB
Blood; 2014 Dec; 124(25):3758-67. PubMed ID: 25320244
[TBL] [Abstract][Full Text] [Related]
2. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation.
Yang HS; Jansen AP; Komar AA; Zheng X; Merrick WC; Costes S; Lockett SJ; Sonenberg N; Colburn NH
Mol Cell Biol; 2003 Jan; 23(1):26-37. PubMed ID: 12482958
[TBL] [Abstract][Full Text] [Related]
3. BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL.
Xia M; David L; Teater M; Gutierrez J; Wang X; Meydan C; Lytle A; Slack GW; Scott DW; Morin RD; Onder O; Elenitoba-Johnson KSJ; Zamponi N; Cerchietti L; Lu T; Philippar U; Fontan L; Wu H; Melnick AM
Cancer Discov; 2022 Aug; 12(8):1922-1941. PubMed ID: 35658124
[TBL] [Abstract][Full Text] [Related]
4. Coordinated regulation of scaffold opening and enzymatic activity during CARD11 signaling.
Wang Z; Hutcherson SM; Yang C; Jattani RP; Tritapoe JM; Yang YK; Pomerantz JL
J Biol Chem; 2019 Oct; 294(40):14648-14660. PubMed ID: 31391255
[TBL] [Abstract][Full Text] [Related]
5. B-cell receptor signaling as a driver of lymphoma development and evolution.
Niemann CU; Wiestner A
Semin Cancer Biol; 2013 Dec; 23(6):410-21. PubMed ID: 24060900
[TBL] [Abstract][Full Text] [Related]
6. Structure of the tandem MA-3 region of Pdcd4 protein and characterization of its interactions with eIF4A and eIF4G: molecular mechanisms of a tumor suppressor.
Waters LC; Strong SL; Ferlemann E; Oka O; Muskett FW; Veverka V; Banerjee S; Schmedt T; Henry AJ; Klempnauer KH; Carr MD
J Biol Chem; 2011 May; 286(19):17270-80. PubMed ID: 21454508
[TBL] [Abstract][Full Text] [Related]
7. CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma.
Decombis S; Bellanger C; Le Bris Y; Madiot C; Jardine J; Santos JC; Boulet D; Dousset C; Menard A; Kervoelen C; Douillard E; Moreau P; Minvielle S; Moreau-Aubry A; Tessoulin B; Roue G; Bidère N; Le Gouill S; Pellat-Deceunynck C; Chiron D
Blood; 2023 Nov; 142(18):1543-1555. PubMed ID: 37562004
[TBL] [Abstract][Full Text] [Related]
8. Broad anti-pathogen potential of DEAD box RNA helicase eIF4A-targeting rocaglates.
Obermann W; Azri MFD; Konopka L; Schmidt N; Magari F; Sherman J; Silva LMR; Hermosilla C; Ludewig AH; Houhou H; Haeberlein S; Luo MY; Häcker I; Schetelig MF; Grevelding CG; Schroeder FC; Lau GSK; Taubert A; Rodriguez A; Heine A; Yeo TC; Grünweller A; Taroncher-Oldenburg G
Sci Rep; 2023 Jun; 13(1):9297. PubMed ID: 37291191
[TBL] [Abstract][Full Text] [Related]
9. RNA aptamers to initiation factor 4A helicase hinder cap-dependent translation by blocking ATP hydrolysis.
Oguro A; Ohtsu T; Svitkin YV; Sonenberg N; Nakamura Y
RNA; 2003 Apr; 9(4):394-407. PubMed ID: 12649492
[TBL] [Abstract][Full Text] [Related]
10. The role of the CBM complex in allergic inflammation and disease.
DeVore SB; Khurana Hershey GK
J Allergy Clin Immunol; 2022 Nov; 150(5):1011-1030. PubMed ID: 35981904
[TBL] [Abstract][Full Text] [Related]
11. In silico study of polyphenols as potential inhibitors of MALT1 protein in non-Hodgkin lymphoma.
Sezer A; Mahmutović L; Akçeşme B
Med Oncol; 2023 Dec; 41(1):37. PubMed ID: 38155268
[TBL] [Abstract][Full Text] [Related]
12. Novel eIF4A1 inhibitors with anti-tumor activity in lymphoma.
Kayastha F; Herrington NB; Kapadia B; Roychowdhury A; Nanaji N; Kellogg GE; Gartenhaus RB
Mol Med; 2022 Sep; 28(1):101. PubMed ID: 36058921
[TBL] [Abstract][Full Text] [Related]
13. mTORC1/S6K1 signaling promotes sustained oncogenic translation through modulating CRL3
Jiao D; Sun H; Zhao X; Chen Y; Lv Z; Shi Q; Li Y; Wang C; Gao K
Elife; 2024 May; 12():. PubMed ID: 38738857
[TBL] [Abstract][Full Text] [Related]
14. HuD stimulates translation via eIF4A.
Chen CY; Shyu AB
Mol Cell; 2009 Dec; 36(6):920-1. PubMed ID: 20064457
[TBL] [Abstract][Full Text] [Related]
15. DOK3 promotes atopic dermatitis by enabling the phosphatase PP4C to inhibit the T cell signaling mediator CARD11.
Loh JT; Teo JKH; Kannan S; Verma CS; Andiappan AK; Lim HH; Lam KP
Sci Signal; 2023 Oct; 16(809):eadg5171. PubMed ID: 37906628
[TBL] [Abstract][Full Text] [Related]
16. Naturally occurring T cell mutations enhance engineered T cell therapies.
Garcia J; Daniels J; Lee Y; Zhu I; Cheng K; Liu Q; Goodman D; Burnett C; Law C; Thienpont C; Alavi J; Azimi C; Montgomery G; Roybal KT; Choi J
Nature; 2024 Feb; 626(7999):626-634. PubMed ID: 38326614
[TBL] [Abstract][Full Text] [Related]
17. A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer.
Cencic R; Im YK; Naineni SK; Moustafa-Kamal M; Jovanovic P; Sabourin V; Annis MG; Robert F; Schmeing TM; Koromilas A; Paquet M; Teodoro JG; Huang S; Siegel PM; Topisirovic I; Ursini-Siegel J; Pelletier J
Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2318093121. PubMed ID: 38232291
[TBL] [Abstract][Full Text] [Related]
18. RNA helicase EIF4A1-mediated translation is essential for the GC response.
Screen M; Matheson LS; Howden AJ; Strathdee D; Willis AE; Bushell M; Sansom O; Turner M
Life Sci Alliance; 2024 Feb; 7(2):. PubMed ID: 38011999
[TBL] [Abstract][Full Text] [Related]
19. Aggressive lymphomas.
Lenz G; Staudt LM
N Engl J Med; 2010 Apr; 362(15):1417-29. PubMed ID: 20393178
[TBL] [Abstract][Full Text] [Related]
20. Phosphatidylserine synthesis controls oncogenic B cell receptor signaling in B cell lymphoma.
Omi J; Kato T; Yoshihama Y; Sawada K; Kono N; Aoki J
J Cell Biol; 2024 Feb; 223(2):. PubMed ID: 38048228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
